Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials
Paper cited by one bottleneck page and eight idea pages, indexed on Europe PMC as PubMed record 23153379 and published in BMC cancer; the citing pages link this DOI, which is how the record was matched.
Overview
Background: In this meta-analysis we aimed to determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPC) for patients with advanced gastric cancer who underwent gastrectomy.
Methods: In accordance with standard meta-analysis procedures, our study included patients who underwent resection for advanced gastric cancer and were randomly allocated to receive either hyperthermic intraperitoneal chemotherapy or control. We searched PubMed (up to November 2011), EMBASE (up to November 2011), Cochrane Database of Systematic Reviews (CDSR), and Cochrane Central Register of Controlled Trials (CCTR) (up to November 2011). Both published and unpublished trials were included in the analysis, and no search restrictions were imposed. There was no language restriction. The results were analyzed using RevMan 5.1 software, which was provided by Cochrane Collaboration.
Results: There were ten randomized controlled trials included in the analysis. A total of 1062 patients with gastric cancer in these studies were divided into the HIPC group (n = 518) and control group (n = 544). A significant improvement in survival was observed in the HIPC groups compared to the control group in the mitomycin C (MMC) subgroup (RR = 0.75, 95%CI 0.65-0.86; P < 0.00001) and the 5-FU group (RR = 0.69, 95%CI 0.52-0.90; P < 0.00001); the total RR was 0.73 (95%CI 0.64-0.83; P < 0.00001). Our findings indicated that HIPC potentially exhibited a lower peritoneal recurrence rate in the HIPC group compared to the control group (RR = 0.45, 95%CI 0.28-0.72; P = 0.001).
Conclusions: Our meta-analysis demonstrated that HIPC may improve the overall survival rate for patients who receive resection for advance gastric cancer potentially, and help to prevent peritoneal local recurrence among patients with serosal invasion in gastric cancer.
Indexed on Europe PMC as PubMed record 23153379 (DOI 10.1186/1471-2407-12-526). Matched by DOI alone: one bottleneck page and eight idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and eight idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- IdeaPayers fund trials of cheaper, shorter or lower-dose versions of expensive treatments
Shares A trials fund reserved for older and multimorbid patients, A fixed share of trial-group funding for getting proven care to patients.
- IdeaTen-year awards for scientists who commit to one hard problem
Shares A dedicated programme for cachexia and treatment toxicity research, Funding follows fashion, not burden.
- IdeaBurden-weighted portfolio targets for every major cancer funder
Shares Judge funding programme officers on burden alignment and trials completed, Funding follows fashion, not burden.
- IdeaStructured exercise prescribed like a drug in all curative-intent cancer care
Shares A survivorship research endowment funded by a levy on curative therapy prices, A dedicated programme for cachexia and treatment toxicity research.
- IdeaA Global Fund for cancer care in low- and middle-income countries
Shares Burden-matched funding for trials led in low- and middle-income countries, Funding follows fashion, not burden.
- IdeaA ring-fenced metastasis programme with metastasis-specific endpoints
Shares Treat brain metastases as a disease with its own trials programme, Funding follows fashion, not burden.
- TechnologyGeriatric assessment
Shares A trials fund reserved for older and multimorbid patients, A dedicated programme for cachexia and treatment toxicity research, A fixed share of trial-group funding for getting proven care to patients.
- TechnologyCardio-oncology
Shares A survivorship research endowment funded by a levy on curative therapy prices, A dedicated programme for cachexia and treatment toxicity research.